Immunic Highlights IMU-856 Gastrointestinal Candidate to Mark International Celiac Day
Immunic Inc's Hella Kohlhof discusses the company’s developments in treating celiac disease and the potential of IMU-856 as a more effective treatment option on International Celiac Day
Celiac disease affects a significant portion of the global population, and the only current treatment is a gluten-free diet, which is not effective for all patients. Immunic's development of IMU-856 offers hope for improving the conditions of celiac disease patients and potentially providing a more effective treatment option.
